| 姜明霞,李 俏,徐兵河.HER2阳性晚期乳腺癌靶向治疗药物分类及临床研究进展[J].中国肿瘤,2024,33(7):583-595. |
| HER2阳性晚期乳腺癌靶向治疗药物分类及临床研究进展 |
| Progress on Classification and Clinical Research of Targeted Drugs for HER2-Positive Advanced Breast Cancer |
| 投稿时间：2023-09-03 |
| DOI：10.11735/j.issn.1004-0242.2024.07.A010 |
|
 |
| 中文关键词: 晚期乳腺癌 人表皮生长因子受体2 靶向治疗 单克隆抗体 抗体偶联药物 |
| 英文关键词:advanced breast cancer human epidermal growth factor receptor 2 targeted therapy monoclonal antibody antibody-drug conjugates |
| 基金项目:中国医学科学院医学与健康科技创新工程（2021-I2M-1-014）；中国医学科学院医学与健康科技创新工程(2022-I2M-JB-009) |
|
| 摘要点击次数: 402 |
| 全文下载次数: 178 |
| 中文摘要: |
| 摘 要：人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）是乳腺癌已知的重要分子靶点。HER2作为原癌基因之一，通常与侵袭性、复发转移及较差预后相关。抗HER2药物曲妥珠单抗的临床应用，大大改善了HER2阳性乳腺癌的诊疗模式和预后，并成为乳腺癌抗HER2靶向治疗的里程碑。HER2阳性晚期乳腺癌患者除存在禁忌情况外，应尽早进行抗HER2治疗。全文就HER2阳性晚期乳腺癌靶向治疗的药物分类及其研究进展作一综述，以期为晚期乳腺癌靶向治疗研究提供新思路。 |
| 英文摘要: |
| Abstract： Human epidermal growth factor receptor 2 (HER2) is an essential molecular target point known for breast cancer. As one of the proto-oncogenes， HER2 is usually associated with invasiveness， recurrence and metastasis， and poor prognosis. The clinical application of trastuzumab (anti-HER2 strategy) has dramatically improved the diagnosis， treatment mode， and prognosis of HER2-positive breast cancer and has become a milestone in anti-HER2-targeted breast cancer therapy. HER2-positive advanced breast cancer (ABC) patients should receive anti-HER2 treatment as soon as possible， except for contraindications. This paper reviews the drug classification and progress of targeted therapy for HER2-positive ABC to provide new insights for the study of targeted therapy for ABC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |